Document is current
Any future updates will be listed below
-
Authors
Ling, Alexander L.
Solomon, Isaac H. http://orcid.org/0000-0003-3432-0902
Landivar, Ana Montalvo
Nakashima, Hiroshi
Woods, Jared K.
Santos, Andres
Masud, Nafisa
Fell, Geoffrey
Mo, Xiaokui http://orcid.org/0000-0002-9797-2687
Yilmaz, Ayse S.
Grant, James
Zhang, Abigail
Bernstock, Joshua D. http://orcid.org/0000-0002-7814-3867
Torio, Erickson http://orcid.org/0000-0003-0958-704X
Ito, Hirotaka
Liu, Junfeng
Shono, Naoyuki
Nowicki, Michal O.
Triggs, Daniel
Halloran, Patrick
Piranlioglu, Raziye http://orcid.org/0000-0003-2450-3887
Soni, Himanshu
Stopa, Brittany
Bi, Wenya Linda http://orcid.org/0000-0002-4635-0247
Peruzzi, Pierpaolo
Chen, Ethan
Malinowski, Seth W.
Prabhu, Michael C.
Zeng, Yu
Carlisle, Anne
Rodig, Scott J.
Wen, Patrick Y.
Lee, Eudocia Quant
Nayak, Lakshmi
Chukwueke, Ugonma http://orcid.org/0000-0003-0598-9535
Gonzalez Castro, L. Nicolas
Dumont, Sydney D.
Batchelor, Tracy
Kittelberger, Kara
Tikhonova, Ekaterina
Miheecheva, Natalia http://orcid.org/0000-0002-6487-5514
Tabakov, Dmitry http://orcid.org/0000-0002-1509-2206
Shin, Nara http://orcid.org/0000-0002-9910-4971
Gorbacheva, Alisa
Shumskiy, Artemy
Frenkel, Felix http://orcid.org/0000-0002-8958-7447
Aguilar-Cordova, Estuardo
Aguilar, Laura K. http://orcid.org/0000-0002-3473-0330
Krisky, David
Wechuck, James
Manzanera, Andrea
Matheny, Chris http://orcid.org/0000-0001-7860-2173
Tak, Paul P.
Barone, Francesca
Kovarsky, Daniel
Tirosh, Itay http://orcid.org/0000-0001-5477-2987
Suvà, Mario L. http://orcid.org/0000-0001-9898-5351
Wucherpfennig, Kai W. http://orcid.org/0000-0002-1829-302X
Ligon, Keith http://orcid.org/0000-0002-7733-600X
Reardon, David A. http://orcid.org/0000-0001-6674-0157
Chiocca, E. Antonio http://orcid.org/0000-0001-5183-1670
- License Information
-
More Information
Article History
Received: 21 February 2023
Accepted: 7 September 2023
First Online: 18 October 2023
Change Date: 3 November 2023
Change Type: Update
Change Details: An amendment to the underlying article code was made to enable an author name to appear correctly in PubMed. In addition, a hyphen was missing in the data availability link, which has now been updated.
Competing interests
: J.D.B. has an equity position in Treovir, an oHSV clinical stage company and is a member of the POCKiT Diagnostics board of scientific advisors; and has a provisional patent (application number 63/273,577) entitled ‘Methods and formulations related to the intrathecal delivery of oncolytic viruses’. W.L.B. consulted for Stryker. P.P. is cofounder and member of the board of directors of Ternalys Therapeutics; he is also named as an inventor on patents related to non-coding RNA technology. P.Y.W. received research support from AstraZeneca/Medimmune, Beigene, Celgene, Chimerix, Eli Lily, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Puma, Servier, Vascular Biogenics and VBI Vaccines and served on advisory boards for AstraZeneca, Bayer, Black Diamond, Boehringer Ingelheim, Boston Pharmaceuticals, Celularity, Chimerix, Genenta, GlaxoSmithKline, Karyopharm, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics and VBI Vaccines, and on data safety monitoring committees for Day One Bio and Novocure. L.N. serves as a consultant for Ono and Brave Bio. L.N.G.C. received research support from Merck (to the Dana-Farber Cancer Institute); he also has received research support from the NIH, the American Society of Clinical Oncology and the Robert Wood-Johnson Foundation. E.Q.L. receives royalties from Wolter Kluwer (Up to Date) and consulting fees from GCAR. T.B. receives clinical trial support from ONO Pharmaceuticals, publishing royalties from UpToDate and Oxford University Press. S.J.R. receives research support from Bristol Myers-Squibb and KITE/Gilead; and is on the scientific advisory board for Immunitas Therapeutics. K.K. is employed by and owns equity in Clearpoint. E. Tikhonova, N. Miheecheva, D. Tabakov, N. Shin, A.G., A. Shumskiy and F.F. are employed by BostonGene and have equity options in BostonGene. E.A.-C. is a founder, board member of and holds equity in Candel Therapeutics. L.K.A. is co-founder and holds equity in Candel Therapeutics. D. Krisky, J.W., A.M., C.M., P.P.T. and F.B. are employees of and hold equity in Candel Therapeutics. I.T. is an advisory board member of Immunitas Therapeutics. M.L.S. and K.W.W. are equity holders, scientific co-founders and advisory board members of Immunitas Therapeutics. D.A.R. is an advisor to Agios, AnHeart Therapeutics, Avita Biomedical, Blue Rock Therapeutics, Bristol Myers Squibb, Boston Biomedical, CureVac, Del Mar Pharma, DNAtrix, Hoffman-LaRoche, Imvax, Janssen, Kiyatec, Medicenna Therapeutics, Neuvogen, Novartis, Novocure, Pyramid, Sumitomo Dainippon Pharma, Vivacitas Oncology and Y-mabs Therapeutics. E.A.C. is an advisor to Amacathera, Bionaut Labs, Genenta, Insightec, DNAtrix, Seneca Therapeutics and Theravir; he has equity options in Bionaut Laboratories, DNAtrix, Immunomic Therapeutics, Seneca Therapeutics and Ternalys Therapeutics; he is co-founder and on the board of directors of Ternalys Therapeutics. Patents related to oHSV and CAN-3110 are under the possession of Brigham and Women’s Hospital with E.A.C. and H.N. named as co-inventors. These patents have been licensed to Candel Therapeutics. Present and future milestone license fees and future royalty fees are distributed to Brigham and Women’s Hospital from Candel. The other authors declare no competing interests.
